In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock ...

Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat. Traditional therapies targeting androgen receptor (AR) signaling have limited ...

Merck MRK announced that EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended granting conditional ...

This case is part of a larger wave of litigation involving PFAS contamination against chemical manufacturers over the health ...

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

EU regulators recommend approval of Merck's drug Welireg for certain patients with VHL disease or advanced kidney cancer.

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy ...

Top Forbes SHOOK advisors pledge $1.5M to fund kidney cancer treatment at Sloan Kettering Cancer Center in New York ...

Despite the notable advancements in cancer pharmacotherapy, such as chemotherapy, targeted therapy, and immunotherapy, which have significantly improved patient survival rates, managing the associated ...

Defective VHL protein is also present in most cases of advanced clear cell renal cell carcinoma (RCC), so a recommendation for belzutifan was issued to also cover this condition. The drug is indicated ...

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.